These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Suppressive effect of oxatomide on the induction of IL2 responsiveness by DF-stimulated lymphocytes from patients with bronchial asthma].
    Author: Yoshizawa I, Nakajima T, Kawano Y, Noma T.
    Journal: Arerugi; 1994 Apr; 43(4):535-43. PubMed ID: 7913315.
    Abstract:
    Oxatomide is an anti-allergic agent having an anti-histamine effect, and has been widely used for clinical purposes. The effect of oxatomide-treatment on the induction of IL2 responsiveness by Df-stimulated lymphocytes was studied in patients with bronchial asthma. Oxatomide alone has almost no effect on lymphocyte activation. Patient's lymphocytes pretreated with 2 to 2000 ng/ml doses of oxatomides for 24 to 48 hours failed to produce Df-induced IL2 responsiveness in a dose-dependent manner. The target cells for oxatomide's suppressive effect were antigen-presenting cells such as macrophages and dendritic cells rather than responder T cells. PPD-induced IL2 responsiveness was also suppressed by the treatment, but the Con A-induced response was not. The results suggest that oxatomide has a slight immunosuppressive capability to block the induction of IL2 responsiveness by Df-stimulated patient's lymphocytes, resulting in the decreased production of such lymphokines as IL2, IL3, IL4, IL5, in a lymphokine cascade of allergic responses, in addition to inhibition of the degranulation and activation of inflammatory cells such as mast cells/basophils and eosinophils.
    [Abstract] [Full Text] [Related] [New Search]